Role of cytokines and chemokines in non-alcoholic fatty liver disease
Top Cited Papers
Open Access
- 1 January 2012
- journal article
- review article
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 18 (8), 727-35
- https://doi.org/10.3748/wjg.v18.i8.727
Abstract
Non-alcoholic fatty liver disease (NAFLD) includes a variety of histological conditions (ranging from liver steatosis and steatohepatitis, to fibrosis and hepatocarcinoma) that are characterized by an increased fat content within the liver. The accumulation/deposition of fat within the liver is essential for diagnosis of NAFLD and might be associated with alterations in the hepatic and systemic inflammatory state. Although it is still unclear if each histological entity represents a different disease or rather steps of the same disease, inflammatory processes in NAFLD might influence its pathophysiology and prognosis. In particular, non-alcoholic steatohepatitis (the most inflamed condition in NAFLDs, which more frequently evolves towards chronic and serious liver diseases) is characterized by a marked activation of inflammatory cells and the upregulation of several soluble inflammatory mediators. Among several mediators, cytokines and chemokines might play a pivotal active role in NAFLD and are considered as potential therapeutic targets. In this review, we will update evidence from both basic research and clinical studies on the potential role of cytokines and chemokines in the pathophysiology of NAFLDKeywords
This publication has 100 references indexed in Scilit:
- Monocyte chemoattractant protein-1 deficiency does not affect steatosis or inflammation in livers of mice fed a methionine–choline-deficient dietLaboratory Investigation, 2010
- C-C Chemokine Receptor 2 (CCR2) Regulates the Hepatic Recruitment of Myeloid Cells That Promote Obesity-Induced Hepatic SteatosisDiabetes, 2010
- Apoptosis and Cytokines in Non-Alcoholic SteatohepatitisClinics in Liver Disease, 2009
- IL-6 Deficiency Attenuates Murine Diet-Induced Non-Alcoholic SteatohepatitisPLOS ONE, 2009
- Antifibrotic Effects of CXCL9 and Its Receptor CXCR3 in Livers of Mice and HumansGastroenterology, 2009
- A randomized controlled pilot study of Pentoxifylline in patients with non-alcoholic steatohepatitis (NASH)Hepatology International, 2008
- Prevalence of Elevated Alanine Aminotransferase Among US Adolescents and Associated Factors: NHANES 1999–2004Gastroenterology, 2007
- MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesityJCI Insight, 2006
- Effects of Etanercept in Patients With the Metabolic SyndromeArchives of Internal Medicine, 2006
- CCR2 modulates inflammatory and metabolic effects of high-fat feedingJCI Insight, 2006